BACKGROUND: Acquisition of additional breast tissue has become integral to breast oncology research. This questionnaire study examines patient willingness to undergo research-dedicated breast biopsies either at time of diagnostic biopsy (T1) or after carcinoma diagnosis has been confirmed and eligibility for a specific study established (T2), and influencing factors thereof. METHODS: Prior to consultation, patients attending breast clinics were recruited to complete a questionnaire examining willingness to undergo an extra fine needle aspirate (FNA) and/or core needle biopsy (CNB) for research either at T1 or T2. Descriptions of FNA and CNB procedures were supplied to those with no prior experience. Patient perspectives towards donating surplus tissue remaining from a diagnostic procedure and/or surgery for future research were also explored. FINDINGS: A total of 100 patients were recruited, 42% with prior history of breast carcinoma (BC), 22% with family history of BC (FHBC) and 65%/42% with previous experience of CNB/FNA respectively. Overall, 57% were willing to undergo additional biopsy at one or both time points. Willingness to undergo additional biopsy was greater for T1 than T2, but equivalent for CNB and FNA (willingness CNB T1, 50% vs T2, 26%, willingness FNA T1 50% vs T2 29%). A statistically significant increase in willingness to undergo CNB and/or FNA at T1 and/or T2 was seen in association with prior diagnosis of BC, FHBC, previous visit to breast clinic and prior experience of breast biopsy. 83% of patients expressed a willingness to allow surplus tissue to be stored in a biobank for future research. INTERPRETATION: Where possible patients should be approached to undergo baseline research biopsies at time of diagnostic process rather than subsequently. Patients do not find FNA more acceptable than core biopsy. Prior exposure to the biopsy procedure increases willingness to undergo research-dedicated biopsies.
BACKGROUND: Acquisition of additional breast tissue has become integral to breast oncology research. This questionnaire study examines patient willingness to undergo research-dedicated breast biopsies either at time of diagnostic biopsy (T1) or after carcinoma diagnosis has been confirmed and eligibility for a specific study established (T2), and influencing factors thereof. METHODS: Prior to consultation, patients attending breast clinics were recruited to complete a questionnaire examining willingness to undergo an extra fine needle aspirate (FNA) and/or core needle biopsy (CNB) for research either at T1 or T2. Descriptions of FNA and CNB procedures were supplied to those with no prior experience. Patient perspectives towards donating surplus tissue remaining from a diagnostic procedure and/or surgery for future research were also explored. FINDINGS: A total of 100 patients were recruited, 42% with prior history of breast carcinoma (BC), 22% with family history of BC (FHBC) and 65%/42% with previous experience of CNB/FNA respectively. Overall, 57% were willing to undergo additional biopsy at one or both time points. Willingness to undergo additional biopsy was greater for T1 than T2, but equivalent for CNB and FNA (willingness CNB T1, 50% vs T2, 26%, willingness FNA T1 50% vs T2 29%). A statistically significant increase in willingness to undergo CNB and/or FNA at T1 and/or T2 was seen in association with prior diagnosis of BC, FHBC, previous visit to breast clinic and prior experience of breast biopsy. 83% of patients expressed a willingness to allow surplus tissue to be stored in a biobank for future research. INTERPRETATION: Where possible patients should be approached to undergo baseline research biopsies at time of diagnostic process rather than subsequently. Patients do not find FNA more acceptable than core biopsy. Prior exposure to the biopsy procedure increases willingness to undergo research-dedicated biopsies.
Authors: Davinia S Seah; Sarah Scott; Hao Guo; Julie Najita; Ruth Lederman; Elizabeth Frank; Jessica Sohl; Zsofia Stadler; Stuart Silverman; Jeffrey Peppercorn; Eric Winer; Steve Come; Nancy U Lin Journal: Oncologist Date: 2015-08-03
Authors: Davinia S Seah; Nabihah Tayob; Jose Pablo Leone; Jiani Hu; Jun Yin; Melissa Hughes; Sarah M Scott; Ruth I Lederman; Elizabeth Frank; Jessica J Sohl; Zsofia K Stadler; Timothy K Erick; Jeffrey Peppercorn; Eric P Winer; Stuart G Silverman; Steven E Come; Nancy U Lin Journal: Breast Cancer Res Treat Date: 2022-01-23 Impact factor: 4.872
Authors: Dennis G Moledina; Bettina Cheung; Lidiya Kukova; Randy L Luciano; Aldo J Peixoto; F Perry Wilson; Sandra Alfano; Chirag R Parikh Journal: Kidney Int Rep Date: 2017-11-20
Authors: Leona M Batten; Indrani Subarna Bhattacharya; Laura Moretti; Joanne S Haviland; Marie A Emson; Sarah E Miller; Monica Jefford; Mairead MacKenzie; Maggie Wilcox; Marie Hyslop; Rachel Todd; Claire F Snowdon; Judith M Bliss Journal: Res Involv Engagem Date: 2018-07-16
Authors: Renée H Fiechter; Janne W Bolt; Sander W Tas; Lisa G M van Baarsen; Marleen G H van de Sande; Caroline J Aalbers; Robert B M Landewé; Mario Maas Journal: Arthritis Res Ther Date: 2022-02-03 Impact factor: 5.156